Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study

Cihan Yurdaydin, Onur Keskin, Çağdaş Kalkan, Fatih Karakaya, Aysun Çalişkan, Ersin Karatayli, Senem Karatayli, A. Mithat Bozdayi, Christopher Koh, Theo Heller, Ramazan Idilman, Jeffrey S. Glenn – 20 November 2017 – In a proof‐of‐concept (POC) study, the oral prenylation inhibitor, lonafarnib (LNF), decreased hepatitis D virus (HDV) RNA during 4 weeks of treatment. Here, we explored optimal LNF regimens.

Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation

Henning Pflugrad, Anna‐Kristina Schrader, Anita Blanka Tryc, Xiaoqi Ding, Heinrich Lanfermann, Elmar Jäckel, Harald Schrem, Jan Beneke, Hannelore Barg‐Hock, Jürgen Klempnauer, Karin Weissenborn – 20 November 2017 – Calcineurin inhibitors (CNIs) frequently induce neurological complications early after orthotopic liver transplantation (OLT). We hypothesize that longterm CNI therapy after OLT causes dose‐dependent cognitive dysfunction and alteration of brain structure.

Memory T cells are significantly increased in rejected liver allografts of rhesus monkeys

Hwajung Kim, Hyeyoung Kim, Sun‐Kyung Lee, Xue‐Li Jin, Tae Jin Kim, Chanho Park, Jae‐Il Lee, Hyo‐Sin Kim, Suk Kyun Hong, Kyung Chul Yoon, Sung Woo Ahn, Kyoung‐Bun Lee, Nam‐Joon Yi, Jaeseok Yang, Kwang‐Woong Lee, Wayne J. Hawthorne, Kyung‐Suk Suh – 18 November 2017 – The rhesus monkey (RM) is an excellent preclinical model in kidney, heart, and islet transplantation that has provided the basis for new immunosuppressive protocols for clinical studies. However, there remain relatively few liver transplantation (LT) models in nonhuman primates.

High mobility group protein B1 controls liver cancer initiation through yes‐associated protein ‐dependent aerobic glycolysis

Ruochan Chen, Shan Zhu, Xue‐Gong Fan, Haichao Wang, Michael T. Lotze, Herbert J. Zeh, Timothy R. Billiar, Rui Kang, Daolin Tang – 17 November 2017 – Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver tumor metabolic reprogramming remains elusive. Here, we provide evidence that high mobility group box 1 (HMGB1), a chromosomal protein, plays a role in the regulation of the Hippo pathway during liver tumorigenesis.

Transferrin as a predictor of survival in cirrhosis

André Viveiros, Armin Finkenstedt, Benedikt Schaefer, Mattias Mandorfer, Bernhard Scheiner, Konrad Lehner, Moritz Tobiasch, Thomas Reiberger, Herbert Tilg, Michael Edlinger, Heinz Zoller – 17 November 2017 – Patients with cirrhosis frequently present with high serum ferritin and low transferrin concentrations, reflecting impaired liver function and inflammation. Recent studies have shown that transferrin and its saturation with iron are Model for End‐Stage Liver Disease–independent predictors of mortality in patients with acute‐on‐chronic liver failure or decompensated cirrhosis.

Subscribe to